{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:14Z","timestamp":1788415934757,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermolysis bullosa (EB) is a rare, inherited skin fragility disorder with significant disease burden and rapidly evolving therapeutic options. Clinical trial recruitment in rare diseases remains challenging; understanding patient perspectives is essential to designing patient-centred protocols. The objective of this study was to explore clinical trial awareness, motivators, and barriers among patients with EB and their caregivers in Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This cross-sectional study recruited participants of all EB subtypes and ages from the Saudi EB Registry. A 40-item structured, self-administered questionnaire assessed clinical background, knowledge and attitudes toward clinical trials, motivators and barriers for participation. Responses were recorded on a five-point Likert scale. Data were analysed using IBM SPSS Statistics version 23.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-five participants were enrolled; 68.6% were younger than 18 years and 57.1% of questionnaires were completed by caregivers. Knowledge about EB clinical trials was low in 80% of participants; the level of knowledge was statistically significantly associated with the desire to participate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Despite low knowledge, willingness to participate was high or very high in 51.4% of participants. Practical motivators ranked highest; travel and accommodation cost coverage and better medical care during the study period were rated as highly important by 94.3% each. Altruistic motivators followed closely; contributing to increased disease knowledge and future improvements for other patients with EB were highly important to 91.4% and 88.6% respectively. The dominant barriers were distance and travel costs and concern about being in the placebo group (65.7% each), followed by lack of clear information about the study protocol (62.9%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the characterisation of clinical trial awareness, motivators, and barriers among patients with EB and their caregivers. Patient education is the most actionable target for improving trial recruitment. The high prioritisation of symptom alleviation underscores the importance of incorporating patient-reported outcome measures as primary or co-primary endpoints in future EB trial design. Trial protocols in EB should minimise travel burden and invasive procedures, address paediatric-specific barriers including route of administration, frequency, and school absenteeism, and incorporate flexible, patient-centred designs to optimise enrolment across the EB community.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1913338","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:13:34Z","timestamp":1788412414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trial awareness and participation attitudes among patients with epidermolysis bullosa and their caregivers: a nationwide cross-sectional study from Saudi Arabia"],"prefix":"10.3389","volume":"13","author":[{"given":"Ashjan","family":"Alheggi","sequence":"first","affiliation":[{"name":"Department of Dermatology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifaleslam A.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"General Medicine Practice Program, Batterjee Medical College","place":["Aseer, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danah","family":"Alali","sequence":"additional","affiliation":[{"name":"General Practitioner, King Faisal Hospital","place":["Al-Ahasa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar","family":"Bukhari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Albargawi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Alkhodair","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology, Department of Pediatrics, King Abdullah Specialized Children\u2019s Hospital","place":["Riyadh, Saudi Arabia"]},{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Research Center, King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wagger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology and EB House Austria, University Hospital of the Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kitzmueller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology and EB House Austria, University Hospital of the Paracelsus Medical University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues","volume":"61","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s13555-024-01227-8","article-title":"Treatment of epidermolysis bullosa and future directions: a review","volume":"14","author":"Danescu","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bjd\/ljac001","article-title":"Efficacy and safety of oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomised double-blind phase of the EASE study","volume":"188","author":"Kern","year":"2023","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","article-title":"Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial","volume":"406","author":"Tang","year":"2025","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","article-title":"Clinical trials in rare disease: challenges and opportunities","volume":"28","author":"Augustine","year":"2013","journal-title":"J Child Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/PPA.S104259","article-title":"Patient involvement in clinical research: why, when, and how","volume":"10","author":"Sacristan","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"B10","doi-asserted-by":"publisher","first-page":"MR000045","DOI":"10.1002\/14651858.MR000045","article-title":"Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis","volume":"10","author":"Houghton","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(06)70576-9","article-title":"Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors","volume":"7","author":"Mills","year":"2006","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-020-01443-3","article-title":"Profiling trial burden and patients\u2019 attitudes to improve clinical research in epidermolysis bullosa","volume":"15","author":"Prodinger","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0197513","DOI":"10.1371\/journal.pone.0197513","article-title":"Mitochondrial disease patient motivations and barriers to participate in clinical trials","volume":"13","author":"Zolkipli-Cunningham","year":"2018","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/healthcare13091044","article-title":"Clinical trial awareness, perceptions, and participation among cancer patients in Saudi Arabia","volume":"13","author":"Alotaibi","year":"2025","journal-title":"Healthcare"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/clinpract13060133","article-title":"Combined results of two cross-sectional surveys on the participation in clinical trials and the e-consent procedure in the landscape of haematology","volume":"13","author":"Heyrman","year":"2023","journal-title":"Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/17407745211048178","article-title":"Incentives and payments in pragmatic clinical trials: scientific, ethical, and policy considerations","volume":"18","author":"Garland","year":"2021","journal-title":"Clin Trials"},{"key":"B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/ecc.12184","article-title":"Hope for a cure and altruism are the main motives behind participation in phase 3 clinical trials","volume":"24","author":"Godskesen","year":"2015","journal-title":"Eur J Cancer Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e66678","DOI":"10.7759\/cureus.66678","article-title":"Genetic implications and management of epidermolysis bullosa in the Saudi Arabian population","volume":"16","author":"Shehata","year":"2024","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ijd.16197","article-title":"The impact of epidermolysis bullosa on the family and healthcare practitioners: a scoping review","volume":"62","author":"Chateau","year":"2023","journal-title":"Int J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-019-1002-z","article-title":"The patient\u2019s view on rare disease trial design: a qualitative study","volume":"14","author":"Gaasterland","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13023-022-02388-5","article-title":"What role can decentralised trial designs play to improve rare disease studies?","volume":"17","author":"Moore","year":"2022","journal-title":"Orphanet J Rare Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:13:35Z","timestamp":1788412415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1913338"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1913338","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1913338"}}